{
  "id": 1767779566451,
  "title": "CHILDHOOD GLAUCOMA: Assessment & Treatment Guide",
  "summary": "Childhood glaucomas are a rare, insidious, yet significant cause of blindness requiring vigilant assessment. This guide covers classification from primary congenital to complex secondary etiologies, alongside current medical and surgical management strategies.",
  "date": "2026-01-07T09:52:46.451Z",
  "data": {
    "title": "CHILDHOOD GLAUCOMA: Assessment & Treatment Guide",
    "summary": "Childhood glaucomas are a rare, insidious, yet significant cause of blindness requiring vigilant assessment. This guide covers classification from primary congenital to complex secondary etiologies, alongside current medical and surgical management strategies.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='4'/><circle cx='50' cy='50' r='15' fill='hsl(215, 90%, 45%)'/><path d='M20 50 Q 50 10 80 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M20 50 Q 50 90 80 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><line x1='50' y1='50' x2='75' y2='25' stroke='hsl(215, 90%, 45%)' stroke-width='2'/></svg>",
    "sections": [
      {
        "title": "Classification: Primary Glaucomas",
        "icon": "category",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "Primary Childhood Glaucomas",
          "branches": [
            "Primary Congenital Glaucoma (PCG; trabeculodysgenesis): Rare (1/10,000 live births). Angle dysgenesis reduces aqueous outflow. Bilateral in 70%. Commoner in ♂ (65%). 10% familial (loci GLC3 A–D). GLC3A gene is CYP1B1 (Chr 2p).",
            "Primary Juvenile Glaucoma: Etiology unknown. Presentation 10th to 35th year of life. Sporadic or familial. Identified genes: CYP1B1 (Chr 2p) and MYOC (Chr 1q)."
          ]
        }
      },
      {
        "title": "Secondary Glaucoma: Developmental & Surgery",
        "icon": "layers",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Anterior segment dysgenesis: Spectrum including Axenfeld–Rieger syndrome and Peters anomaly. Glaucoma occurs in about 50%.",
          "Aniridia (iridotrabeculodysgenesis): Abnormal or absent iris tissue. Associated with glaucoma in up to 75%.",
          "Lens/Surgery-related: Congenital cataract surgery associated with glaucoma in up to 60%. Risk highest in early surgery and aphakic patients. IOL withholding vs. early surgery association is unknown.",
          "Posterior segment abnormalities: Persistent fetal vasculature syndrome and ROP (via 2° angle closure mechanism)."
        ]
      },
      {
        "title": "Secondary Glaucoma: Tumors & Disease",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Tumour-related: Reduced outflow via mechanical clogging, TM debris, 2° haemorrhage, or rubeotic glaucoma. Includes Anterior (JXG, medulloepithelioma), Posterior (retinoblastoma), or Systemic (leukaemia).",
          "Phakomatoses: Sturge–Weber (up to 50% ipsilateral risk, highest with upper/lower lid naevus flammeus). NF-1 (increased risk with ipsilateral neurofibroma).",
          "Connective tissue disease: Marfan’s, homocystinuria, and Weill–Marchesani (via abnormal TM or lens block).",
          "Uveitis: Chronic uveitis (e.g., JIA) results in 2° glaucoma, usually relatively late onset."
        ]
      },
      {
        "title": "Clinical Presentation",
        "icon": "visibility",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Classic Triad: Watering eye(s), Photophobia, Blepharospasm.",
          "Ocular Signs: Increased IOP (iIOP), Corneal oedema.",
          "Structural Changes: Enlargement of cornea/globe (buphthalmos if onset <4y), Breaks in Descemet’s membrane (Haab striae)."
        ]
      },
      {
        "title": "Additional Diagnostic Features",
        "icon": "search",
        "type": "table",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Ophthalmic Clues",
            "Systemic Clues"
          ],
          "rows": [
            [
              "Posterior embryotoxon, leukoma, anterior iris strands, iris hypoplasia",
              "Naevus flammeus (Sturge–Weber), neurofibromas (NF-1 or -2)"
            ],
            [
              "Aniridia, iris cyst/tumour, iritis, Lisch nodules (NF-1), cataract",
              "Marfanoid habitus (Marfan’s, homocystinuria)"
            ],
            [
              "Ectopia lentis, aphakia, persistent fetal vasculature",
              "Brachydactyly (Weill–Marchesani), abnormal dentition"
            ],
            [
              "Ciliary body tumours, retinal masses",
              "Umbilical hernia / failed periumbilical skin involution (Rieger)"
            ]
          ]
        }
      },
      {
        "title": "Measuring IOP in Children",
        "icon": "speed",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Technique choice depends on age and cooperation.",
          "iCare (Rebound Tonometer): Dramatically reduced EUA needs; no anesthetic required; well tolerated.",
          "Tonopen / Perkins: Can be used with topical anaesthetic in infants.",
          "Goldmann Applanation Tonometry (GAT): Remains the gold standard.",
          "EUA (Examination Under Anesthesia): Required if cooperation fails. Inhalational anesthesia lowers IOP progressively (more than ketamine sedation)."
        ]
      },
      {
        "title": "The IOP and CCT Relationship",
        "icon": "biotech",
        "type": "table",
        "layout": "half_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Corneal Condition",
            "IOP Measurement Effect"
          ],
          "rows": [
            [
              "Higher CCT / Thicker Cornea (Aphakic, Aniridia, Micro-cornea)",
              "Overestimates IOP (Measured > Actual)"
            ],
            [
              "Lower CCT / Thinner Cornea (Keratoconus, Keratoglobus)",
              "Underestimates IOP (Measured < Actual)"
            ]
          ]
        }
      },
      {
        "title": "General Treatment Strategy",
        "icon": "settings_suggest",
        "type": "process",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "1. Titrate treatment based on IOP (interpreted via CCT), disc appearance, corneal diameter, and axial length.",
          "2. Utilize perimetry and RNFL OCT in older, cooperative children.",
          "3. Medical treatment: Often used to temporize or avoid surgery (though less effective than in adults).",
          "4. Surgical treatment: Preferred based on glaucoma type and severity."
        ]
      },
      {
        "title": "Medical Management Warnings",
        "icon": "error",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Brimonidine (α2-agonist): CONTRAINDICATED in children <2y due to CNS depression.",
          "Apraclonidine: May be safer in younger children but still causes drowsiness.",
          "Systemic Carbonic Anhydrase Inhibitors (CAIs): Can cause lethargy, decreased appetite, and impaired growth; use for short periods only.",
          "Adherence Issues: Major problem; use combination preparations and non-stinging drops to improve compliance."
        ]
      },
      {
        "title": "Medical Options Summary",
        "icon": "medication",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Topical β-blockers",
          "Carbonic anhydrase inhibitors (CAIs)",
          "Prostoglandin analogues (PGAs)"
        ]
      },
      {
        "title": "Surgical Treatments (Table 18.33)",
        "icon": "precision_manufacturing",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Procedure",
            "Indications",
            "Advantages/Disadvantages"
          ],
          "rows": [
            [
              "Goniotomy and/or Trabeculotomy",
              "Congenital glaucoma (trabeculodysgenesis). >90% control at 5y. Clear cornea needed for goniotomy.",
              "Low complication rate; maintains anatomical route; possible in small eyes. Less effective for non-trabeculodysgenesis."
            ],
            [
              "Trabeculectomy ± augmentation",
              "Refractory glaucoma.",
              "Risks: Blebitis, leak, hypotony, endophthalmitis. High failure rate in children due to fibrosis; impractical post-op requirements."
            ],
            [
              "Aqueous shunting (Tubes)",
              "Refractory glaucoma; especially aphakic glaucoma.",
              "Fewer post-op procedures. Risks: Tube migration, plate extrusion, corneal touch, endophthalmitis, strabismus."
            ],
            [
              "Cyclodestructive laser",
              "Surgical failure; when surgery is contraindicated due to comorbidities.",
              "Minimal post-op management. Risks: Hypotony, phthisis, inflammation, retinal detachment (rare if titrated)."
            ]
          ]
        }
      },
      {
        "title": "Surgical Definitions",
        "icon": "book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Goniotomy: Incision of uveal trabecular meshwork under gonioscopic view. Trabeculotomy/canaloplasty: Cannulation of Schlemm's canal ab externo to disrupt the internal wall/TM. Aqueous shunts: Silicone tube from AC to episcleral explant. Trabeculectomy: New drainage channel to subconjunctival space. Cycloablation: Endoscopic or trans-scleral laser to reduce aqueous production."
      },
      {
        "title": "References & Citations",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "9. European Glaucoma Society. Terminology and guidelines for glaucoma, 3rd edition. Savona: Dogma; 2008. 10. Coppens G et al. The safety and efficacy of glaucoma medications in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009;46:12–18. Content adapted from Chapter 18 Paediatric Ophthalmology, pp. 895-897."
      }
    ]
  },
  "chapterId": "pediatric",
  "seqId": 43,
  "_serverSynced": true
}